Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The transcription factor Foxa2, which is key for the hepatic control of glucose metabolism, is now shown in this report to also be crucial for proper bile acid homestasis in the liver, as well as to be misregulated in human cholestatic diseases.
Studies of gene expression in lung cancer have the potential to affect patient care, but the general applicability of the derived classifiers is unclear. David Beer and his colleagues now analyze more than 400 lung tumors from subjects at six institutions using eight different classifiers and show that the combination of molecular and clinical data best predicts patient survival (pages 812–813).
BACE is an enzyme necessary for the generation of neurotoxic amyloid-β in Alzheimer's disease. Claes Wahlestedt and his colleagues identify a noncoding RNA that is upregulated in the brains of individuals with Alzheimer's disase. This noncoding RNA increases expression of BACE, driving amyloid-β generation and possibly disease progression.
tPA is a clot-buster used to treat stroke, but if it's given too late after stroke onset, it can cause complications like hemorrhage. Daniel Lawrence and his colleagues show that a US Food and Drug Administration–approved kinase inhibitor, Gleevec, can prevent this side effect, thereby extending tPA's therapeutic window.
The Ca2+-permeable channel TRPM2 stimulates monocytes to produce chemokines in response to reactive oxygen species, and channel inhibition attenuates inflammatory disease in mice. TRPM2 could be a new target for treating inflammatory diseases.